Immunoglobulin.

Replacement indication

Primary and secondary immunodeficiency (PID / SID).

Pediatric PID data from 3 years; use under 3 years has not been established.

Canadian label dosing

IVIG. PID/SID: 0.2–0.8 g/kg every 3–4 weeks; adjust to clinical response and IgG levels.

Administration

IV infusion; follow the monograph’s initial rate and escalation schedule.

Pack sizes & access

2.5 g / 25 mL; 5 g / 50 mL; 10 g / 100 mL; 20 g / 200 mL; 40 g / 400 mL.

Routine supply: CBS and Héma-Québec.

Ingredients & IgA

L-proline; water for injection, with hydrochloric acid and sodium hydroxide for pH adjustment.

IgA: ≤25 micrograms/mL.

The 2025 label advises weighing benefit and risk in hyperprolinemia.

Storage

Store at 2–25°C until the labelled expiry. Keep in the original carton; do not freeze.

Replacement indication

Primary and secondary humoral immunodeficiency.

Pediatric use described at ages 1–18 years; SC evidence is limited.

Canadian label dosing

IVIG. PID: 0.1–0.6 g/kg every 3–4 weeks. SID regimens are indication-specific; see the monograph.

SCIG. PID/SID IV-to-SC switch: initial weekly grams = prior IV grams × 1.37 ÷ interval in weeks. Adjust to clinical response and IgG levels.

Administration

IV or SC administration; follow the route-specific preparation, site volumes and infusion rates.

Pack sizes & access

2.5 g / 25 mL; 5 g / 50 mL; 10 g / 100 mL; 20 g / 200 mL; 40 g / 400 mL.

Routine supply: CBS; confirm Québec access.

Ingredients & IgA

Glycine and water for injection.

IgA: ≤84 micrograms/mL (average 46).

Storage

2–8°C; may be kept at ≤25°C for up to 6 months within the original expiry, then use or discard. Do not freeze.

Replacement indication

Primary and secondary immunodeficiency, including CLL and pediatric HIV.

Studied above 24 months of age; no dedicated pediatric studies.

Canadian label dosing

IVIG. PID: initial 0.4–0.8 g/kg, then 0.2–0.8 g/kg every 2–4 weeks. SID: 0.2–0.4 g/kg every 3–4 weeks; transplant regimens differ.

Administration

IV only in Canada. Follow Canadian infusion rates; foreign packaging may show other routes.

Pack sizes & access

2.5 g / 25 mL; 5 g / 50 mL; 10 g / 100 mL; 20 g / 200 mL; 30 g / 300 mL.

The monograph’s 1 g vial is not on current routine supply lists.

Routine supply: CBS and Héma-Québec.

Ingredients & IgA

Glycine and water for injection.

IgA: ≤140 micrograms/mL.

Storage

2–8°C. Below 25°C: expiry is the earlier of 12 months after removal or 24 months after manufacture; record the new date. Do not rerefrigerate or freeze.

Replacement indication

Primary immunodeficiency; B-cell CLL with hypogammaglobulinemia and/or recurrent bacterial infections.

Pediatric experience above 24 months of age; no dedicated pediatric studies.

Canadian label dosing

IVIG. PID: initial 0.2–0.4 g/kg; subsequent monthly doses individualized to response. The label’s ≥0.1 g/kg monthly minimum is not a usual maintenance target. B-cell CLL: 0.4 g/kg every 3–4 weeks.

Administration

Reconstitute with the supplied sterile water, not saline. Follow concentration-specific preparation, IV rates and post-reconstitution limits.

Pack sizes & access

5 g kit.

Reconstitute the 5 g kit to 5% (50 mg/mL) or 10% (100 mg/mL).

Routine supply: CBS; confirm Québec access.

Ingredients & IgA

Glycine, glucose, human albumin, sodium chloride, polyethylene glycol, polysorbate 80, octoxynol 9 and tri-n-butyl phosphate.

IgA: ≤2.2 micrograms/mL at 5% (double at 10%).

Low IgA content does not establish safety after a severe immunoglobulin reaction.

Storage

Store the unopened kit at ≤25°C. Do not freeze. Reconstituted product has separate handling and storage limits; see the monograph.

Replacement indication

Primary and secondary humoral immunodeficiency.

Pediatric use described at ages 1–18 years; SC evidence is limited.

Canadian label dosing

IVIG. PID: 0.1–0.6 g/kg every 3–4 weeks. SID regimens are indication-specific; see the monograph.

SCIG. PID/SID IV-to-SC switch: initial weekly grams = prior IV grams × 1.37 ÷ interval in weeks. Adjust to clinical response and IgG levels.

Administration

IV or SC administration; follow the route-specific preparation, site volumes and infusion rates.

Pack sizes & access

20 g / 200 mL.

Other labelled sizes (2.5, 5, 10 and 40 g) require local supply confirmation.

Routine supply: CBS; confirm Québec access.

Ingredients & IgA

Glycine and water for injection.

IgA: ≤84 micrograms/mL (average 46).

Storage

2–8°C; may be kept at ≤25°C for up to 6 months within the original expiry, then use or discard. Do not freeze.